Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases
Restricted accessResearch articleFirst published online September, 2013
Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases
The prognosis of peritoneal metastases from colorectal cancer has recently improved with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Although outcomes are further improved when early stage peritoneal metastases are treated, adjuvant hyperthermic intraperitoneal chemotherapy has never been thoroughly addressed. This prospective pilot study assessed feasibility, safety and efficacy of hyperthermic intraperitoneal chemotherapy combined with primary curative surgery in colorectal cancer at high risk for peritoneal metastases.
Methods
Twelve patients were prospectively selected according to predetermined risk factors for the development of peritoneal metastases. Patients underwent conventional colon surgery, closed-abdomen mitomycin-C plus cisplatin-based hyperthermic intraperitoneal chemotherapy, and cytoreductive surgical procedures, as needed.
Results
Preoperative tumor-related risk factors were confirmed by intraoperative findings and pathological examination in all patients: minimal synchronous peritoneal metastases (n = 2), synchronous ovarian metastases (n = 1), positive peritoneal washing cytology (n = 2), primary tumor directly invading other organs (n = 6), or penetrating visceral peritoneum (n = 1). Major morbidity occurred in 2 patients and operative death in none. Median follow-up was 49 months (range, 22–72). Peritoneal metastases occurred in 1 patient and distant metastases in 2. Five-year overall survival was 83.3%.
Conclusions
Preoperative/early intraoperative assessment can reliably identify colorectal cancer patients at high risk for peritoneal metastases. Adjuvant hyperthermic intraperitoneal chemotherapy is well tolerated and safe. These preliminary results would support the design of future phase-III trials of adjuvant hyperthermic intraperitoneal chemotherapy.
ChuD.Z., LangN.P., ThompsonC., OsteenP.K., WestbrookK.C.: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer, 63: 364–647, 1989.
KoppeM.J., BoermanO.C., OyenW.J., BleichrodtR.P.: Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg, 243: 212–222, 2006.
5.
Segelman1J., GranathF., HolmT., MachadoM., MahtemeH., MartlingA.: Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg, 99: 699–705, 2012.
6.
FolprechtG., KohneC-H, LutzM.: Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. In: Peritoneal Carcinomatosis: A Multidisciplinary Approach — Cancer Treatment and Research, CeelenW.P. (Ed), pp 425–440, Springer, New York, 2007.
7.
VerwaalV.J., van RuthS., de BreeE., van SloothenG.W., van TinterenH., BootH., ZoetmulderF.A.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol, 21: 37–43, 2003.
8.
EliasD., LefevreJ.H., ChevalierJ., BrouquetA., MarchalF., ClasseJ.M., FerronG., GuilloitJ.M., MeeusP., GoéréD., BonastreJ.: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol, 27: 681–685, 2009.
9.
FrankoJ., IbrahimZ., GusaniN.J., HoltzmanM.P., BartlettD.L., ZehHJ3rd: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer, 116: 3756–3762, 2010.
10.
FrankoJ., ShiQ., GoldmanC.D., PockajB.A., NelsonG.D., GoldbergR.M., PitotH.C., GrotheyA., AlbertsS.R., SargentD.J.: Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. J Clin Oncol, 30: 263–267, 2012.
11.
MahtemeH., HanssonJ., BerglundA., PåhlmanL., GlimeliusB., NygrenP., GrafW.: Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br Journal of Cancer, 90: 403–407, 2004.
12.
YanT.D., BlackD., SavadyR., SugarbakerP.H.: Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol, 24: 4011–4019, 2006.
13.
CaoC., YanT.D., BlackD., MorrisD.L.: A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol, 16: 2152–2165, 2009.
14.
EliasD., GillyF., BoutitieF., QuenetF., BerederJ.M., MansveltB., LorimierG., DubèP., GlehenO.: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol, 28: 63–68, 2010.
González-MorenoS., González-BayónL., Ortega-PérezG., González-HernandoC.: Imaging of peritoneal carcinomatosis. Cancer J, 15: 184–189, 2009.
17.
YanT.D., BlackD., SugarbakerP.H., ZhuJ., YonemuraY., PetrouG., MorrisD.L.: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol, 14: 2702–2713, 2007.
18.
ChungT.S., ChangH.J., JungK.H., ParkS.Y., LimS.B., ChoiH.S., JeongS.Y.: Role of surgery in the treatment of ovarian metastases from colorectal cancer. J Surg Oncol, 100: 570–574, 2009.
19.
TanK.L., TanW.S., LimJ.F., EuK.W.: Krukenberg tumors of colorectal origin: a dismal outcome-experience of a tertiary center. Int J Colorectal Dis, 25: 233–238, 2010.
20.
SugarbakerP.H., GianolaF.J., SpeyerJ.C., WesleyR., BarofskyI., MeyersC.E.: Prospective randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surg, 98: 414–422, 1985.
21.
FujiwaraA., NouraS., OhueM., ShingaiT., YamadaT., MiyashiroI., OhigashiH., YanoM., IshikawaO., KamiuraS., TomitaY.: Significance of the resection of ovarian metastasis from colorectal cancers. J Surg Oncol, 102: 582–587, 2010.
22.
EliasD., HonoréC., DumontF., DucreuxM., BoigeV., MalkaD., BurtinP., DromainC., GoéréD.: Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg, 254: 289–293, 2011.
23.
SugarbakerP.H.: Peritonectomy procedures. Ann Surg, 221: 29–42, 1995.
24.
DeracoM., BarattiD., KusamuraS., LaterzaB., BalestraM.R.: Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol, 100: 321–328, 2009.
25.
SobinL.H., GospodarowiczM.K., WittekindC.H. (eds): International Union Against Cancer. TNM Classification of Malignant Tumours.7th edn, Wiley-Blackwell, West Sussex, 2009.
26.
ScheithauerW., KornekG.V., MarczellA., KarnerJ., SalemG., GreinerR., BurgerD., StögerF., RitschelJ., KovatsE., VischerH.M., SchneeweissB., DepischD.: Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer, 77: 1349–1354, 1998.
27.
NouraS., OhueM., ShingaiT., KanoS., OhigashiH., YanoM., IshikawaO., TakenakaA., MurataK., KameyamaM.: Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol, 18: 396–404, 2011.
SammartinoP., SibioS., BiacchiD., CardiM., AccarpioF., MingazziniP., RosatiM.S., CornaliT., Di GiorgioA.: Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract, 2012: 141585, 2012.
30.
GrossmannI., KlaaseJ.M., AvenariusJ.K., de HinghI.H., MastboomW.J., WiggersT.: The strengths and limitations of routine staging before treatment with abdominal CT in colorectal cancer. BMC Cancer, 11: 433, 2011.
31.
ChuaT.C., YanT.D., SaxenaA., MorrisD.L.: Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg, 249: 900–907, 2009.
